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Abstract
Background: Human chromosomes are capped and stabilized by telomeres. Telomere length regulates a ‘cellular
mitotic clock’ that defines the number of cell divisions and hence, cellular life span. This study aimed to synthesize
the evidence on the association between peripheral blood leucocytes (PBL) telomere length and the risk of
colorectal cancer (CRC).
Methods: We searched relevant studies in electronic databases. When two or more observational studies reported
the same outcome measures, we performed pooled analysis. All the analyses were performed on PBL using PCR.
The odds ratio (OR) and its 95% confidence interval (CI) were used to assess the strength of association.
Results: Seven studies (with 8 datasets) were included in this meta-analysis; 3 prospective studies, 3 retrospective
studies and 1 study with a separate prospective and retrospective designs. The pooled analysis of 4 prospective
studies (summary OR 1.01, 95% CI: 0.77–1.34, I2:30%) and 4 retrospective studies (summary OR 1.65, 95% CI: 0.96–2.83,
I2:96%) showed no relationship between PBL telomere length and the CRC risk. A subgroup analysis of 2 prospective
studies exclusively on females also showed no association between PBL telomere length and the CRC risk (summary
OR, 1.17, 95% CI:0.72–1.91, I2:57%).
Conclusion: The current analysis is insufficient to provide evidence on the relationship between PBL telomere length
and the risk of CRC. Findings suggest that there may be a complex relationship between PBL telomere length and
the CRC risk or discrepancy between genetics, age of patients and clinical studies. Future well powered, large
prospective studies on the relationship between telomere length and the risk of CRC, and the investigations of the
biologic mechanisms are recommended.
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Background
Human chromosomes are capped and stabilized by telo-
meres, which not only protect them from damage but
also have a role in regulating cellular senescence. After
reaching a critical length, telomeres experience a double
DNA change and cells will eventually enter (replication)
senescence or cell death [1, 2], which may be due to a
loss of chromosomal integrity [3]. Laboratory observa-
tions showed that telomere of human somatic cells act as
a “mitotic clock”, shortening with advancing age [1]. The
exhaustion of proliferative potential of telomere, which is
known as cellular senescence, occurred when telomeres
cannot fulfil their normal protective functions [4].
There were an estimated 14.1 million cancer cases
around the world in 2012. Of these, colorectal cancer
(CRC) was the third most common cancer, accounting
1.36 million new case [5]. A considerable number of
studies investigated the association between telomere
length and human cancers including CRC. However,
these individual studies reported inconsistently. Previous
reviews in telomere sizes in cancer have reported CRC as
a part [6–8], or were narrative reviews [9, 10]. Human
telomere length vary with age or cell types [11] and animal
models have shown that this may have diverse effects in
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various organ systems [12]. Since the publication of these
reviews, there has been a surge of published studies which
assessed the association between telomere length and
CRC. Thus, a meta-analysis addressing CRC and telomere
length would be a useful addition to the current informa-
tion in this area. Meta-analysis is a particular statistical
strategy for bringing together the results of several studies
(i.e. independent but ‘comparable’ studies) to produce a
single estimate [13]. On the whole, the objective of the
present study was to synthesize the evidence of published
studies on the association between peripheral blood leuco-
cytes (PBL) telomere length and the CRC risk.
Methods
The present study adhered to the preferred reporting
items for systematic reviews and meta-analyses (PRISMA)
statements [14].
Study search
We searched the relevant studies in the electronic data-
bases such as PubMed, EMBASE, CANCERLIT, DARE
(Database of Abstracts of Reviews of Effects), CINAHL,
Web of Knowledge and Google Scholar. In initial
searches, we used the broad search strategy ‘telomere’
OR ‘telomere length’ AND ‘cancer’ OR ‘carcinoma’ AND
‘risk’ OR ‘epidemiology’ OR ‘pooled analysis’ OR ‘colon
cancer’ OR ‘rectum cancer’ OR ‘colorectal cancer’. We
modified the search strategy according to the require-
ments of different databases. Search was limited to
publications in English through 7th January 2016. We
manually checked the reference lists of the relevant re-
views and the included studies to find additional studies
which could not be captured in electronic search.
Study selection
Studies were eligible if they (i) reported on associations
between baseline telomere length and CRC (as defined by
histology), (ii) included controls (in case-control studies)
who were cancer-free or healthy person, (iii) selected
participants (in cohort studies) with pre-existing CRC,
(iv) selected samples from PBL, and (v) provided suf-
ficient data to estimate the strength of association.
As described elsewhere [15] both prospective and
retrospective designs were considered. In retrospective
studies, telomere length was measured in DNA samples
collected after diagnosis of CRC. In prospectively de-
signed studies, this was done from participants prior to
diagnosis or development of CRC. Retrospective studies
included case-control and cross-sectional studies, while
prospective studies included nested case-control and
prospective cohort studies. Studies were excluded if they
did not meet the inclusion criteria. For studies that en-
rolled overlapping participants, only the studies with lar-
ger samples were included.
Data extraction
Two authors independently screened the titles and ab-
stracts, and assessed the full text, if deemed relevant for
this review. Any discrepancy was resolved by discussion.
The selected articles were reviewed to determine their
eligibility for the current review. The data from the in-
cluded studies were extracted using a piloted data ex-
traction sheet. We extracted the following information
from each of the included studies: author, year of publi-
cation, year of study, country, study design, type of CRC
(i.e. colon cancer, rectal cancer, CRC), sample type, sam-
ple source, assay and outcomes reported. Any disagree-
ment in data extraction was resolved by consensus or
involving a senior author.
Methodological assessments
One author appraised the methodological quality of each
included studies using Newcastle-Ottawa Scale (NOS)
[16]. This was cross-checked by another author. The
study quality rating of each study was judged based on
the participants’ selection (four stars), the comparability
of the study groups (two stars) and the assessment of ex-
posure (three stars). The highest total score for a study
was nine. Any discrepancy between the two assessors
was resolved by consensus and by taking advice from a
senior author.
Statistical analysis
We extracted study specific OR and corresponding
95% confidence interval (CI) from the included stud-
ies (i.e. for the association between shortest Q4 vs
longest Q1, Q1 vs Q4 or below vs above the median
length). We assumed that the relative risk (RR) from
cohort studies approximates the odds ratio (OR) from
case-control studies [17]. We transformed OR and its
95% CI into natural log OR and its standard error
(SE) of log OR before meta-analysis [18]. Statistical
heterogeneity between studies was assessed with the
I2 test, which indicates the variation in effect esti-
mates due to (true) heterogeneity rather than within-
study error [19]. A value of ≥50% indicates substantial
heterogeneity [18, 19]. A random-effects model with
inverse variance weighting was used to calculate the
pooled OR and its 95% CI as there was substantial
heterogeneity between studies [20]. Otherwise, we used a
fixed-effect model.
All statistical analyses were performed with RevMan
5.3 [21]. Dataset is freely available from the correspond-
ing author (CN) for non-commercial purpose.
Results
Study characteristics
The study selection process is provided in a flowchart
(Additional file 1: Figure S1). After screening titles and
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abstracts, 20 full texts were retrieved; seven studies (with
8 data sets) [22–28] were selected for inclusion in this
meta-analysis. Thirteen studies [29–41] were excluded
as they did not meet the inclusion criteria. Reasons for
the exclusion were summarized in Additional file 2:
Table S1.
Table 1 presents the characteristics of the included
studies. Three studies were prospectively designed stud-
ies [22, 23, 25], three studies were retrospective studies
[26–28], and one study was done with prospective and
retrospective designs, separately [24]. Two studies
assessed exclusively with female participants [23, 25],
while one study with males [22]. These studies were
published between 2009 and 2014. Age of participants
ranged from 18 to 82 years.
Two studies each were done in China [25, 28] and the
UK [24, 25] The remaining three studies were from the
United States [22, 23, 27]. Three studies [22, 23, 27]
have provided separate components in CRC, indicat-
ing most were colon cancer (70.3–78.8%) and the rest
were rectal cancer (21.2–29.7%). In all studies, DNA
sources was extracted from PBL and used qPCR to
measure the telomere length. The Pellatt study used
immortalized cell lines for colon cancer and PBL for
rectal cancer [26]. Methodological quality of the in-
cluded studies was provided (Additional file 3: Table S2).
All studies were high in methodological quality, achieving
7–9 stars [22–28].
Summary estimates
Overall, there is no significant relationship between telo-
mere length measured in PBL DNA and the CRC risk in
both retrospective and prospective studies. The sum-
mary OR in 4 retrospective studies was 1.65 (95% CI:
0.96–2.83) with substantial statistical heterogeneity
(I2:96%). The summary OR (1.01, 95% CI: 0.77–1.34) in
four prospective studies was also with significant hetero-
geneity (I2:30%) (Fig. 1).
Subgroup analysis
When we analyzed two prospective studies solely on fe-
male participants [23, 25], there also was no significant
association between telomere length and the CRC risk
(summary OR, 1.17; 95% CI:0.72–1.91, I2:57%) (Fig. 2).
Due to a paucity of data, we were not able to perform
subgroup analysis with age groups.
Discussion
Based on the available data, the present study has pro-
vided insights into the relationship between PBL telo-
mere length and the CRC risk. Due to small number of
studies the results from the current analysis is insuffi-
cient to provide evidence on the role of PBL telomere
length and CRC risk.
Telomere length in CRC
Findings in this review showed there is no significant re-
lationship between telomere length measured in PBL
DNA and the CRC risk in both retrospective and pro-
spective studies. There are many possible reasons for
such relationship. The risk of CRC might be elevated by
shorter or longer length of telomere, indicating a U-
shape association [25]. It is possible that loss of telo-
meric DNA in relation to degradation or incomplete
replication is apparently balanced by telomere elongation
[1, 42, 43]. This also implied that telomere length in an
‘appropriate range’ may be necessary to maintain
chromosomal stability and normal programmed cell
death - functions which are protective against tumour
development [25, 44]. It has been hypothesized that cells
with long telomeres may favour a delayed cell senes-
cence and apoptosis, leading to an increased chance of
various genetic and environmental insults and subse-
quent accumulations of genetic abnormalities attributed
to a higher risk of carcinogenic transformation [25].
On the other hand, the relationship between short
telomere length and the CRC risk is biologically plaus-
ible [28]. A large proportion of human cancers are made
up of cells with very short telomeres (5 kb), which is at-
tributable to telomere dysfunction [45]. Although the
exact mechanism is not fully understood, it is possible
that, in some situations, cells with critically short telo-
mere length may reactivate the telomerase enzyme, and
this further promotes malignant transformation [28].
The putative pathway for telomere-associated neoplasia
is that shortening of telomeres in the colorectal mucosa
increases the chromosomal susceptibility to instability
[40] as well as the microsatellite instability [47].
Reasons for no significant associations in our findings
also rest on discrepancy of the study participants such as
gender, age, life styles and the study design related fac-
tors (e.g. sample size, prospective or retrospective study).
For instance, an association of telomere length and the
CRC development in age-depending manner was shown
in an individual study included in this analysis [28].
Older patients with shorter telomeres may be prone to
an increased risk for various types of cancers due to
telomere crisis [28] and subsequent chromosomal aber-
rations [25] and the diseases that result [25]. Extremely
long telomere in younger individuals may be indicative
of dysregulation in telomere regulation process [28].
We found a change in the effect estimates in a sub-
group analysis solely with females. This highlighted that
hormonal influence (estrogen) on the length of telomere
needed to be given due attention in interpreting the re-
sults. Studies documented that the rate of terminal re-
striction fragment length shortening per year in men
was significantly greater than that in women [45]. An
estrogen-responsive element is present in telomerase


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Naing et al. BMC Cancer  (2017) 17:24 Page 4 of 7
reverse transcriptase (hTERT), so the hormone can
stimulate telomerase [46]. This might have reduced the
shortening of telomere. Another possible mechanism is
in the light of reactive oxygen species (ROS), which are
number of reactive molecules and free radicals derived
from molecular oxygen. As such, hydrogen peroxide and
other ROS accelerate telomere erosion at least in cul-
tured cells. Women are known to produce fewer reactive
oxygen species [42] and this might contribute to less
telomere attrition.
Most of the primary studies in this review have es-
timated an individual’s telomere length from a single
blood collection. In a study, multiple measurements
showed a good reliability (intraclass correlation coeffi-
cient 0.64) indicating a one-time measurement is a
good representation of an individual’s telomere length
within a short period of time [48]. Hence, a one-time
determination in the primary studies would not affect
the confidence in the effect estimate of the current
review.
Fig. 1 Forest plot of association between telomere length and the colorectal cancer risk
Fig. 2 Forest plot of a subgroup analysis solely on female participants
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Study limitations and strengths
There are some limitations that need to be acknowl-
edged. Although we had done an exhaustive literature
search, it was possible that some publications might
have been overlooked, especially when abstracts in
English were not available. Variation in sample collection
time in relation to study design among included studies
is a concern. Samples in the prospective study were col-
lected (many) years before diagnosis and therefore
changes in participant’s diet and lifestyle related factors
and drug history (e.g. treatment with estrogen in
women) overtime could have influenced telomere length,
or conversely telomere length could be influenced by
diagnosis and treatment in the retrospectively designed
study [24, 27].
Variation in measurement methods of telomere
lengths in the primary studies could have affected the ef-
fect estimates. This was, however, not the case in the
present review as all studies applied qPCR for the meas-
urement of telomere length. Stage-specific relationship
could not be analysed as staging of disease with Dukes’
or TNM systems had been provided inconsistently in a
few studies. This might lead to a misclassification bias in
interpreting the results.
Since relevant data were limited, we could not adjust
for confounding factors. For instance, age of patients
was likely to be a confounding factor for the association
between PBL telomere length and the CRC risk. It is dif-
ficult to render the pooled analysis stratified by age
groups, which were not consistently classified among
these studies. Individual studies [45, 49] as well as a sys-
tematic review had suggested an interaction between as-
pirin or non-steroidal anti-inflammatory drug use [49, 50]
and genes encoding transcription factor [49] or a com-
bined effect of life style with gene encoding [27] in onco-
genesis, inflammatory and drug metabolic pathways in
relation to risk of CRC [50]. Hence, our results might be
influenced by these confounding factors.
Due to a small number of studies with limited sample
sizes, there is a limited power to detect a true difference of
telomere length between cases and controls. It calls for fu-
ture well designed, large prospective studies in this field.
Conclusion
The current analysis is insufficient to provide evidence
on the relationship between PBL telomere length and
the risk of CRC. Findings suggest that there may be a
complex relationship between PBL telomere length and
CRC risk, suggesting a U-shaped relationship or discrep-
ancy between genetics, age of patients and clinical stud-
ies. Future well powered, large prospective studies on
the relationship between PBL telomere length and the
risk of CRC, and the investigations of the biologic mech-
anisms are recommended.
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